Pfizer AstraZeneca takeover: Insider warns that acquisition could be ‘devastating’ for research

Exclusive: Pfizer’s former head of research slams his old company as it raises its controversial bid for British firm

The row over Pfizer’s £63 billion takeover bid for the British drugs company AstraZeneca intensified last night as the predator’s own former top scientist railed against the way the US firm’s takeovers destroy research teams and stop the creation of new medicines.

Dr John LaMattina’s concerns about the damage his former company’s takeover sprees were doing to medical laboratories around the world fuelled fresh condemnation of the Viagra maker’s assault on AstraZeneca, which employs 7,000 staff in the UK and is a key part of the life sciences industry.

Yesterday, ministers appeared to give the deal their blessing after Pfizer gave assurances that it would not pull the plug on AstraZeneca’s jobs and research plans.

But critics, mindful of how the US food giant Kraft reneged on promises not to close a UK factory after it was allowed to buy Cadbury Schweppes in 2010, remain unconvinced.

Dr LaMattina retired as president of global research and development at Pfizer after 30 years’ service. He later published a paper in the academic journal Nature Reviews Drug Discovery, declaring: “In major mergers today, not only are R&D cuts made, but entire research sites are eliminated. Nowhere is this more evident than with Pfizer.”

Significantly, he said such “devastating” mergers should “be concerning to patients”, as well as doctors, taxpayers and other stakeholders, “particularly bearing in mind recent cutbacks in areas of research such as antibacterial drugs and neuroscience”.

Read more:  The town that Pfizer built up – and knocked down
AstraZeneca investors press for talks after it spurns Pfizer again
AstraZeneca knows there is no room for sentiment as Pfizer circles  

His comments were underlined by leading scientists warning that major takeover deals risked the entire UK life sciences’ premium world status.

“The UK has been a world leader in medicines research and development, but recent closures and restructuring put this position under threat,” chief scientists at the Royal Societies of biology, pharmacology, chemistry and biochemistry warned in a joint open letter.

Former minister Michael Heseltine and Lord Sainsbury also voiced concerns yesterday about the lack of protection for important UK companies from overseas takeover.

Dr LaMattina, who is currently a senior scientist at the US medicine developer PureTech, wrote his article in 2011 but last night told The Independent: “I could have written that article today: the only difference between 2011 is that I’d have more data. If you’re in R&D right now, at either company, you’re going to be worried. In a lot of these acquisitions there are dramatic cuts, and that’s going to happen here as well.”

He predicted drug discovery programmes in their early stages would be disrupted or even abandoned altogether and highlighted AstraZeneca’s divisions looking for cancer treatments as particularly vulnerable.

Yesterday, Pfizer increased its takeover offer price from £60bn to £63bn – or £50 per AstraZeneca share – but the company’s board rejected it as being too low and refused even to meet to discuss the offer. Most shareholders agreed the offer remains too low, but were optimistic that Pfizer can be made to pay more.

Another concern of AstraZeneca’s board was that the bid was driven more by Pfizer’s desire to avoid US taxes than any wider strategic view of the business.

Pfizer admits a main rationale is tax avoidance. The company has a pool of billions of dollars accrued outside the US, which it does not want to bring back to America because of corporation tax on overseas earnings. Spending the money on a takeover means it can avoid the US tax.

But Pfizer says the takeover’s rationale is also about growing the two businesses.

In an open letter to the Prime Minister yesterday, Pfizer’s chief executive Ian Read praised the “golden triangle” for research of Oxford, Cambridge and London, and pledged to complete AstraZeneca’s planned £300m Cambridge campus. At least a fifth of the combined company’s total R&D workforce would be in the UK, he said.

Science minister David Willetts told The Independent these assurances showed the success of the Government’s “hard-nosed and muscular” talks with the US company. He said he and Chancellor George Osborne had both met the Pfizer boss this week, while the Business Secretary, Vince Cable, had spoken with him about his plans for UK jobs and investment .

Mr Willetts acknowledged, however, that some in the science community are concerned.

The Institute of Directors said politicians should stay away from the deal and leave it to shareholders to decide. “It is misleading to present AstraZeneca as some kind of UK national champion… It is run by a Frenchman and chaired by a Swede,” it said.

However, it added that AstraZeneca’s board should take into account concerns about whether a deal based on tax considerations was best for its shareholders.

The Pfizer way: ‘An alarming trend’

In his article criticising the trend for major pharmaceutical mergers, Dr John LaMattina listed the large research centres Pfizer had closed since it began its aggressive spree of takeovers in 1999 – including its controversial closure in 2011 of its hi-tech site in Sandwich, Kent.

“These sites housed thousands of scientists, and many major drugs [including Viagra] were discovered there. The same pattern has been observed after most of the mergers and acquisitions by other major pharmaceutical companies during the past decade,” he wrote.

Dr LaMattina added that the number of new medicines being invented around the world were directly correlated with the number of drug companies operating, saying: “Now, with so many fewer major companies involved in pharmaceutical R&D, the chances of success in the industry overall are likely to be dropping precipitously.”

He cited Pfizer’s takeovers of Warner-Lambert, Pharmacia and Wyeth as well as “multiple smaller companies”.

“Industry consolidation has resulted in less competition and less investment in R&D,” he said. “At a time when there is a major need for new treatments for conditions such as Alzheimer’s disease, drug resistant infections and diabetes, such a trend is alarming.”

News
people Biographer says cinema’s enduring sex symbol led a secret troubled life
News
newsGlobal index has ranked the quality of life for OAPs - but the UK didn't even make it into the top 10
News
people

Kirstie Allsopp has waded into the female fertility debate again

News
In 2006, Pluto was reclassified as a 'dwarf planet'
scienceBut will it be reinstated?
PROMOTED VIDEO
News
people
News
Researchers say a diet of fatty foods could impede smell abilities
scienceMeasuring the sense may predict a person's lifespan
Sport
footballArsenal 4 Galatasaray 1: Wenger celebrates 18th anniversary in style
News
peopleStella McCartney apologises over controversial Instagram picture
News
Gillian Anderson was paid less than her male co-star David Duchovny for three years while she was in the The X-Files until she protested and was given the same salary
people

Gillian Anderson lays into gender disparity in Hollywood

Life and Style
Laid bare: the Good2Go app ensures people have a chance to make their intentions clear about having sex
techCould Good2Go end disputes about sexual consent - without being a passion-killer?
News
ebooksAn unforgettable anthology of contemporary reportage
Arts and Entertainment
Richard Burr remains the baker to beat on the Great British Bake Off
tvRichard remains the baker to beat as Chetna begins to flake
Life and Style
fashionThe Secret Angels all take home huge sums - but who earns the most?
News
i100
Arts and Entertainment
Amazon has added a cautionary warning to Tom and Jerry cartoons on its streaming service
tv
News
The village was originally named Llansanffraid-ym-Mechain after the Celtic female Saint Brigit, but the name was changed 150 years ago to Llansantffraid – a decision which suggests the incorrect gender of the saint
newsA Welsh town has changed its name - and a prize if you can notice how
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Trainee Recruitment Consultant - Birmingham - Real Staffing

£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...

Trust Accountant - Kent

NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...

Graduate Recruitment Consultant - 2013/14 Grads - No Exp Needed

£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...

Law Costs

Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...

Day In a Page

Italian couples fake UK divorce scam on an ‘industrial scale’

Welcome to Maidenhead, the divorce capital of... Italy

A look at the the legal tourists who exploited our liberal dissolution rules
Tom and Jerry cartoons now carry a 'racial prejudice' warning on Amazon

Tom and Jerry cartoons now carry a 'racial prejudice' warning on Amazon

The vintage series has often been criticised for racial stereotyping
An app for the amorous: Could Good2Go end disputes about sexual consent - without being a passion-killer?

An app for the amorous

Could Good2Go end disputes about sexual consent - without being a passion-killer?
Llansanffraid is now Llansantffraid. Welsh town changes its name, but can you spot the difference?

Llansanffraid is now Llansantffraid

Welsh town changes its name, but can you spot the difference?
Charlotte Riley: At the peak of her powers

Charlotte Riley: At the peak of her powers

After a few early missteps with Chekhov, her acting career has taken her to Hollywood. Next up is a role in the BBC’s gangster drama ‘Peaky Blinders’
She's having a laugh: Britain's female comedians have never had it so good

She's having a laugh

Britain's female comedians have never had it so good, says stand-up Natalie Haynes
Sistine Chapel to ‘sing’ with new LED lights designed to bring Michelangelo’s masterpiece out of the shadows

Let there be light

Sistine Chapel to ‘sing’ with new LEDs designed to bring Michelangelo’s masterpiece out of the shadows
Great British Bake Off, semi-final, review: Richard remains the baker to beat

Tensions rise in Bake Off's pastry week

Richard remains the baker to beat as Chetna begins to flake
Paris Fashion Week, spring/summer 2015: Time travel fashion at Louis Vuitton in Paris

A look to the future

It's time travel fashion at Louis Vuitton in Paris
The 10 best bedspreads

The 10 best bedspreads

Before you up the tog count on your duvet, add an extra layer and a room-changing piece to your bed this autumn
Arsenal vs Galatasaray: Five things we learnt from the Emirates

Arsenal vs Galatasaray

Five things we learnt from the Gunners' Champions League victory at the Emirates
Stuart Lancaster’s long-term deal makes sense – a rarity for a decision taken by the RFU

Lancaster’s long-term deal makes sense – a rarity for a decision taken by the RFU

This deal gives England a head-start to prepare for 2019 World Cup, says Chris Hewett
Ebola outbreak: The children orphaned by the virus – then rejected by surviving relatives over fear of infection

The children orphaned by Ebola...

... then rejected by surviving relatives over fear of infection
Pride: Are censors pandering to homophobia?

Are censors pandering to homophobia?

US film censors have ruled 'Pride' unfit for under-16s, though it contains no sex or violence
The magic of roundabouts

Lords of the rings

Just who are the Roundabout Appreciation Society?